Risk factors for a positive culture at 2 months of pulmonary TB treatment
| Culture conversion before 2 months | Positive culture at 2 months | |||
|---|---|---|---|---|
| N=438 | N=47 | Unadjusted OR (95% CI), p value | Adjusted OR (95% CI), p value | |
| Age over 60 years | 117/438 (26.7) | 10/47 (21.3) | 0.74 (0.36 to 1.54), 0.421 | |
| BMI | ||||
| BMI<18.5 | 111/438 (25.3) | 16/47 (34.0) | 1 | |
| 18.5≤BMI<25 | 280/438 (63.9) | 28/47 (59.6) | 0.83 (0.45 to 1.54), 0.556 | |
| 25≤BMI | 47/438 (10.7) | 3/47 (6.4) | 0.57 (0.17 to 1.90), 0.358 | |
| Smoking status | ||||
| Non-smoker | 244/438 (55.7) | 17/47 (36.2) | 1 | 1 |
| Past smoker | 59/438 (13.5) | 9/47 (44.7) | 1.52 (0.70 to 3.31), 0.290 | 1.55 (0.61 to 3.91), 0.355 |
| Current smoker | 135/438 (30.8) | 21/47 (44.7) | 1.81 (0.99 to 5.34), 0.056 | 1.49 (0.70 to 3.18), 0.307 |
| Symptom score ≥4 | 69/438 (15.8) | 16/47 (34.0) | 2.76 (1.43 to 5.32), 0.002 | 1.07 (0.51 to 2.23), 0.865 |
| Status of DM | ||||
| Non-DM | 339/438 (77.4) | 28/47 (59.6) | 1 | 1 |
| Controlled-DM | 38/438 (8.7) | 2/47 (4.3) | 0.64 (0.15 to 2.78), 0.549 | 0.54 (0.12 to 2.50), 0.537 |
| Uncontrolled-DM | 61/438 (13.9) | 17/47 (36.2) | 3.37 (1.74 to 6.54), <0.001 | 2.11 (1.03 to 4.31), 0.042 |
| Positive smear | 194/438 (44.3) | 42/47 (89.4) | 10.57 (4.10 to 27.21), <0.001 | 6.12 (2.17 to 17.25), 0.001 |
| Drug resistant (any drug) | 43/437 (9.8) | 3/46 (6.5) | 0.64 (0.19 to 2.15), 0.466 | |
| Cavity | 170/438 (38.8) | 34/47 (72.3) | 4.12 (2.12 to 8.04), <0.001 | 1.33 (0.60 to 2.94), 0.488 |
| Consolidation | 259/438 (59.1) | 37/47 (78.7) | 2.56 (1.24 to 5.28), 0.007 | 1.46 (0.66 to 3.20), 0.352 |
| Multi-lobe involvement* | 128/438 (29.2) | 27/47 (57.4) | 3.27 (1.77 to 6.04), <0.001 | 1.54 (0.77 to 3.08), 0.218 |
| Comorbidity† | 64/438 (14.6) | 7/47 (9.9) | 1.02 (0.44 to 2.38), 0.959 | |
| Compliance <95% | 27/436 (6.2) | 5/47 (10.6) | 1.80 (0.66 to 4.93), 0.223 | |
Data are presented as the number (%) of subjects, unless otherwise indicated.
*Multi-lobe involvement indicates lung involvement of more than three lobes.
†Comorbidities include end-stage renal disease, heart disease and cancer.
BMI, body mass index (kg/m2).